Auro Laboratories Ltd
Incorporated in 1989, Auro Laboratories Limited is into the manufacturing of Active Pharmaceutical Ingredients (APIs), specializing in Diabetes therapy. The company also also undertakes Toll/Custom Manufacturing for API's and Intermediates on contract basis.
Key API Products of Auro Labs are:[1]
- Metformin Hydrochloride
- Chlorzoxzone
- Chlorphenamine Maleate
- Market Cap ₹ 144 Cr.
- Current Price ₹ 231
- High / Low ₹ 307 / 112
- Stock P/E 23.4
- Book Value ₹ 69.6
- Dividend Yield 0.00 %
- ROCE 20.4 %
- ROE 20.5 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 116 days to 89.4 days
Cons
- Stock is trading at 3.32 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 2.76% over past five years.
- Company has a low return on equity of 12.9% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
44.28 | 33.74 | 32.65 | 27.91 | 35.47 | 40.79 | 46.82 | 43.79 | 54.25 | 50.87 | 52.89 | 53.64 | 38.86 | |
41.01 | 30.95 | 29.71 | 25.11 | 31.03 | 34.43 | 39.83 | 37.51 | 43.01 | 46.24 | 48.50 | 42.96 | 30.32 | |
Operating Profit | 3.27 | 2.79 | 2.94 | 2.80 | 4.44 | 6.36 | 6.99 | 6.28 | 11.24 | 4.63 | 4.39 | 10.68 | 8.54 |
OPM % | 7.38% | 8.27% | 9.00% | 10.03% | 12.52% | 15.59% | 14.93% | 14.34% | 20.72% | 9.10% | 8.30% | 19.91% | 21.98% |
0.06 | 0.06 | 0.24 | 0.42 | 0.53 | 0.51 | 0.96 | 0.97 | 0.76 | 1.09 | 0.94 | 1.50 | 1.33 | |
Interest | 1.85 | 1.53 | 1.66 | 1.66 | 1.18 | 1.21 | 0.87 | 0.58 | 0.46 | 0.83 | 0.81 | 0.74 | 0.65 |
Depreciation | 0.72 | 0.74 | 0.72 | 0.68 | 0.86 | 0.93 | 1.01 | 1.02 | 1.04 | 1.02 | 1.07 | 1.09 | 1.09 |
Profit before tax | 0.76 | 0.58 | 0.80 | 0.88 | 2.93 | 4.73 | 6.07 | 5.65 | 10.50 | 3.87 | 3.45 | 10.35 | 8.13 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 72.01% | 25.16% | 27.51% | 27.96% | 31.62% | 26.61% | 28.99% | 24.64% | |
0.77 | 0.58 | 0.80 | 0.88 | 0.82 | 3.53 | 4.40 | 4.05 | 7.18 | 2.84 | 2.44 | 7.79 | 6.16 | |
EPS in Rs | 1.24 | 0.93 | 1.28 | 1.41 | 1.32 | 5.66 | 7.06 | 6.50 | 11.52 | 4.56 | 3.91 | 12.50 | 9.88 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 3% |
3 Years: | 0% |
TTM: | -26% |
Compounded Profit Growth | |
---|---|
10 Years: | 30% |
5 Years: | 12% |
3 Years: | 3% |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | 41% |
5 Years: | 34% |
3 Years: | 26% |
1 Year: | 77% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 17% |
3 Years: | 13% |
Last Year: | 20% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 |
Reserves | 0.09 | 0.67 | 1.47 | 2.35 | 3.18 | 6.75 | 11.18 | 15.27 | 22.35 | 25.29 | 27.97 | 35.73 | 37.13 |
16.75 | 14.80 | 16.41 | 12.62 | 4.95 | 9.20 | 8.09 | 3.16 | 3.16 | 13.78 | 6.41 | 26.25 | 34.22 | |
6.75 | 5.14 | 4.67 | 4.49 | 12.45 | 8.23 | 7.97 | 7.68 | 10.15 | 9.66 | 15.38 | 17.52 | 6.45 | |
Total Liabilities | 29.82 | 26.84 | 28.78 | 25.69 | 26.81 | 30.41 | 33.47 | 32.34 | 41.89 | 54.96 | 55.99 | 85.73 | 84.03 |
10.68 | 10.51 | 9.80 | 9.13 | 13.00 | 13.02 | 14.59 | 14.24 | 13.56 | 13.61 | 12.62 | 22.15 | 21.61 | |
CWIP | 0.00 | 0.06 | 0.82 | 3.33 | 0.23 | 1.07 | 0.12 | 0.12 | 0.13 | 3.68 | 7.67 | 32.68 | 39.86 |
Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
19.09 | 16.22 | 18.11 | 13.18 | 13.53 | 16.27 | 18.71 | 17.93 | 28.15 | 37.62 | 35.65 | 30.85 | 22.51 | |
Total Assets | 29.82 | 26.84 | 28.78 | 25.69 | 26.81 | 30.41 | 33.47 | 32.34 | 41.89 | 54.96 | 55.99 | 85.73 | 84.03 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.46 | 4.48 | -0.78 | 7.88 | 6.49 | 6.05 | 6.87 | 9.30 | 12.82 | -6.59 | 3.28 | 18.81 | |
-0.52 | -0.56 | -0.73 | -2.44 | -2.20 | -3.04 | -3.19 | -2.21 | -3.51 | -5.34 | -5.08 | -38.67 | |
-0.79 | -2.99 | 0.53 | -5.34 | -3.81 | -1.77 | -1.83 | -5.52 | -0.46 | 9.79 | -8.18 | 19.09 | |
Net Cash Flow | 0.15 | 0.93 | -0.98 | 0.09 | 0.47 | 1.24 | 1.86 | 1.58 | 8.85 | -2.14 | -9.98 | -0.77 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 66.52 | 46.95 | 94.80 | 66.04 | 79.13 | 74.90 | 66.26 | 48.18 | 49.12 | 97.65 | 85.57 | 91.11 |
Inventory Days | 72.37 | 115.33 | 89.37 | 86.72 | 21.65 | 22.00 | 42.98 | 60.54 | 32.60 | 47.32 | 120.27 | 113.24 |
Days Payable | 64.73 | 62.97 | 56.12 | 72.03 | 80.26 | 78.26 | 66.19 | 70.67 | 73.51 | 54.12 | 117.41 | 85.34 |
Cash Conversion Cycle | 74.17 | 99.30 | 128.05 | 80.73 | 20.52 | 18.64 | 43.05 | 38.04 | 8.20 | 90.86 | 88.44 | 119.01 |
Working Capital Days | 89.27 | 94.12 | 138.51 | 97.17 | 67.20 | 64.70 | 63.46 | 51.09 | 33.84 | 123.56 | 134.64 | 89.41 |
ROCE % | 11.71% | 9.43% | 10.74% | 11.21% | 23.06% | 32.51% | 29.11% | 24.84% | 38.87% | 12.20% | 9.92% | 20.38% |
Documents
Announcements
- Financial Results For The Quarter And Half Year Ended September 30, 2024 1d
-
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024.
5 Nov - Board meeting on November 11 to approve financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
20 Oct - Auro Laboratories Limited has submitted the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 issued by the Registrar and Share Transfer Agent …
-
Closure of Trading Window
1 Oct - Closure of trading window for financial results.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Aug - Auro Laboratories Limited has submitted the newspaper publication of Financial Results for the Quarter ended June 30, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:[1]
a) Active Pharmaceutical Ingredients:
Anti-Diabetics, Anti-Histamines, Muscle Relaxants, Diuretics, Anti Fungal, Anti Ulcer, Anti Fungal, Anti Ulcer, Iodine Supplement, Iron Supplement, Anti Malaria, Analgesics, Antacids, Anti Inflammatory, Specialty Chemicals, etc.
b) Intermediates: [2]
Few Intermediates which are used in APIs are Glibenclamide, Ketoconazol, Sildenafil Citrate, and Citalopram